secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELI LILLY & Co (LLY)
CIK:        0000059478
Form:       8-K
Filed at:   2025-02-06T23:59:59+00:00
Accession:  0000059478-25-000037
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lilly Q4 2024 revenue up 45% to $13.53B, EPS $4.88; 2025 guidance of $58-61B revenue
--------------------------------------------------------------------------------

- Q4 revenue $13.53B (+45% YoY); reported EPS $4.88 (+102%); non-GAAP EPS $5.32 (+114%).
- Revenue growth driven by volume from Mounjaro and Zepbound; non-incretin revenue grew 20%.
- 2025 guidance: revenue $58.0-61.0B, reported EPS $22.05-23.55, non-GAAP EPS $22.50-24.00.
- Pipeline: FDA approved Zepbound for OSA and Omvoh for Crohn's; Kisunla approved in China.
- Board authorized $15B share repurchase program and 15% dividend increase.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/59478/000005947825000037/0000059478-25-000037-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/59478/000005947825000037/lly-20250206.htm
  HTML page:      https://secwatch.observer/filing/0000059478-25-000037

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer